Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price lowered by Stifel Nicolaus from $145.00 to $125.00 in a report published on Tuesday, The Fly reports. Several other equities research analysts have also commented on the stock. Royal Bank of Canada raised their price target on shares of Neurocrine Biosciences from $106.00 to $108.00 […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price boosted by Royal Bank of Canada from $106.00 to $108.00 in a report issued on Monday, The Fly reports. A number of other equities analysts have also commented on the stock. Citigroup decreased their price objective on shares of Neurocrine Biosciences from $127.00 to $122.00 […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its price target cut by stock analysts at Stifel Nicolaus from $145.00 to $125.00 in a report released on Tuesday, The Fly reports. Stifel Nicolaus’ price target would suggest a potential upside of 34.12% from the stock’s previous close. NBIX has been the topic of several other research […]
BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,414 shares of the company’s stock, valued at approximately $527,000. A number of other institutional investors […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation […]